Prognostic value of the Scottish inflammatory prognostic score in ST-Segment elevation myocardial infarction
Biomarkers in Medicine, vol.20, no.5, pp.275-284, 2026 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 20 Issue: 5
- Publication Date: 2026
- Doi Number: 10.1080/17520363.2026.2659655
- Journal Name: Biomarkers in Medicine
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
- Page Numbers: pp.275-284
- Keywords: major adverse cardiac events, primary percutaneous coronary intervention, risk stratification, Scottish inflammatory prognostic score, ST-segment elevation myocardial infarction
- Eskisehir Osmangazi University Affiliated: Yes
Abstract
Aims: The Scottish Inflammatory Prognostic Score (SIPS), has emerged as a simple inflammation-based biomarker; however, its prognostic value in ST-segment elevation myocardial infarction (STEMI) has not been well established. This study aimed to evaluate the prognostic utility of SIPS for predicting long-term major adverse cardiac events (MACE) in STEMI patients. Materials and methods: We included 829 STEMI patients between 2018 and 2024. SIPS was categorized as low (0 points), moderate (1 point), or high risk (2 points). The primary endpoint was time-to-first MACE, defined as a composite of all-cause mortality, non-fatal myocardial infarction, stroke, or cardiovascular hospitalization, using Cox proportional hazards models, competing risk analysis, and measures of incremental discrimination. Results: During follow-up, MACE occurred in 293 patients (35.3%), with a stepwise increase across SIPS categories (23%, 40%, and 63%; p < 0.001). SIPS independently predicted MACE in multivariable analysis (HR per point: 1.62, 95% CI 1.35–1.94; p < 0.001). Discriminative performance was moderate (AUC = 0.655). SIPS remained independently associated with MACE in hierarchical multivariable and competing risk analyses and provided incremental prognostic value beyond clinical predictors. Conclusion: SIPS is an independent predictor of long-term MACE in STEMI patients after PPCI and may serve as a simple and cost-effective tool for early risk stratification.